GUIDELINES FOR THE USE OF SPECIFIC MONOCLONAL ANTIBODIES (PALIVIZUMAB) FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS IN SLOVENIA

  • Marko Pokorn Klinika za infekcijske bolezni in vročinska stanja Klinični center Japljeva 2 1525 Ljubljana
  • Milan Čižman Klinika za infekcijske bolezni in vročinska stanja Klinični center Japljeva 2 1525 Ljubljana
  • Janez Primožič Klinični oddelek za otroško kirurgijo in intenzivno terapijo Klinični center Zaloška 7 1525 Ljubljana
  • Janez Babnik Klinični oddelek za perinatologijo Ginekološka klinika Klinični center Šlajmerjeva 3 1525 Ljubljana
  • Silvo Kopriva Služba za pulmologijo Pediatrična klinika Klinični center Vrazov trg 1 1525 Ljubljana
  • Zdravko Roškar Klinični oddelek za pediatrijo Splošna bolnišnica Maribor Ljubljanska ul. 5 2000 Maribor

Abstract

Background. Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections in children under 12 months of age. Premature children and those with chronic lung disease are at increased risk for severe RSV infection. In 1998, palivizumab, a monoclonal antibody was registered in the US for the prevention of RSV infections in at-risk children. Widespread use of palivizumab is limited by its high price.

Conclusions. In most countries guidelines for the use of palivizumab were set at the national level according to the local epidemiological data on the epidemiology of RSV infections in premature children. At present, a prospective study on the epidemiology of RSV infections in children in Slovenia has been going on and it will be finished in 2003. Slovenian guidelines for the use of palivizumab are presented in the article – these will need to be changed according to the results of the study.

Downloads

Download data is not yet available.

References

Henderson RW, Collier AM, Clyde WA Jr., Denny FE. Respiratory syncytial virus infections, reinfections and immnity. A prospective, longitudinal study in young children. N Engl J Med 1979; 300: 530–4.

Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis associated hospitalisations among US children, 1980–1996. JAMA 1999; 282: 1440–6.

Simoes EAF, Rieger CHL. RSV infection in developed and developing countries. Infect Med 1999; 16: Suppl G: 11–7.

Brandenburg AHU, Jeannet PY, Steensel-Moll HA et al. Local variability in respiratory syncytial virus disease severity. Arch Dis Child 1997; 77: 410–4.

The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531–7.

Groothuis JR for the Northern Hemisphere Expanded Access Study Group. Safety and tolerance of palivizumab administration in a large Northern Hemisphere trial. Pediatr Infect Dis J 2001; 20: 628–30.

Anon. Synagis revisited. Med Lett 2001; 43: 13–4.

Joffe S, Ray TG, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999; 104: 419–27.

Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM. Respiratory syncytial virus and premature infants born at 32 weeks gestation and earlier. Hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med 2000; 154: 55–61.

Clark SJ, Beresford MW, Subhedar NV, Shaw NJ. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch Dis Child 2000; 83: 313–6.

Duppenthaler A, Gorgievski Hrisoho M, Aebi C. Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants. Swiss Med Wkly 2001; 131: 146–51.

Prevention of respiratory syncytial virus infections: Indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102: 1211–6.

Carbonell-Estrany X, Guiffre L, Kimpen J et al. Guidelines for the use of Synagis (palivizumab), a humanized monoclonal antibody, for the prevention of respiratory syncytial virus disease in high-risk infants: A consensus opinion. Infect Med 1999; 16: Suppl G: 29–33.

Swedish Consensus Group. Management of infections caused by respiratory syncytial virus. Scand J Infect Dis 2001; 33: 323–8.

Arbeitsgruppe Neonatologie der österreichischen Gesellschaft für Kinderund Jugendheilkunde. Prävention der Respiratory syncytial Virus (RSV) Infektion bei Frühgeborenen mit Palivizumab (Synagis). Monatschrift Kinderheilkd 2001: 176–9.

Resch B, Gusenleitner W, Müller W. The impact of respiratory syncytial virus infection: a prospective evaluation in hospitalized infants below 24 months of age. In: 5th World Congress of Perinatal Medicine. Barcelona, 2001. Book of abstracts. Abstract No. 220. Barcelona, 2001.

How to Cite
1.
Pokorn M, Čižman M, Primožič J, Babnik J, Kopriva S, Roškar Z. GUIDELINES FOR THE USE OF SPECIFIC MONOCLONAL ANTIBODIES (PALIVIZUMAB) FOR THE PREVENTION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTIONS IN SLOVENIA. TEST ZdravVestn [Internet]. 1 [cited 5Aug.2024];71(10). Available from: http://vestnik-dev.szd.si/index.php/ZdravVest/article/view/1641
Issue
Vol 71 No 10 (2002): October
Section
Quality and safety


The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.

The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory

The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.

The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.

The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.